Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alanine-serine-cysteine transporter 2 (ASCT2), encoded by the SLC1A5 gene, is a sodium-dependent neutral amino acid transporter. It mediates the exchange of small neutral amino acids, primarily glutamine, alanine, and serine, across the plasma membrane. ASCT2 plays a crucial role in cancer metabolism by supplying glutamine for cell growth and proliferation and is a potential therapeutic target. While cysteine can bind, it is a potent inhibitor rather than a transported substrate. Inhibitors like GPNA and V9302 are being developed as anticancer agents.
Inhibition of glutamine transport
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alanine-serine-cysteine transporter 2 (ASCT2).